- Home
- GAMB vs ASMB Comparison
GAMB vs ASMB Comparison
Compare GAMB & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAMB
- ASMB
- Stock Information
- Founded
- GAMB 2006
- ASMB 2005
- Country
- GAMB Jersey
- ASMB United States
- Employees
- GAMB N/A
- ASMB N/A
- Industry
- GAMB Services-Misc. Amusement & Recreation
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- GAMB Consumer Discretionary
- ASMB Health Care
- Exchange
- GAMB Nasdaq
- ASMB Nasdaq
- Market Cap
- GAMB 273.9M
- ASMB 225.9M
- IPO Year
- GAMB 2021
- ASMB 2010
- Fundamental
- Price
- GAMB $7.11
- ASMB $30.12
- Analyst Decision
- GAMB Strong Buy
- ASMB Strong Buy
- Analyst Count
- GAMB 8
- ASMB 5
- Target Price
- GAMB $15.13
- ASMB $44.25
- AVG Volume (30 Days)
- GAMB 723.9K
- ASMB 139.5K
- Earning Date
- GAMB 11-13-2025
- ASMB 11-07-2025
- Dividend Yield
- GAMB N/A
- ASMB N/A
- EPS Growth
- GAMB N/A
- ASMB N/A
- EPS
- GAMB 0.40
- ASMB N/A
- Revenue
- GAMB $147,655,000.00
- ASMB $33,247,000.00
- Revenue This Year
- GAMB $38.41
- ASMB $14.29
- Revenue Next Year
- GAMB $11.58
- ASMB N/A
- P/E Ratio
- GAMB $17.94
- ASMB N/A
- Revenue Growth
- GAMB 27.57
- ASMB 54.77
- 52 Week Low
- GAMB $7.06
- ASMB $7.75
- 52 Week High
- GAMB $17.14
- ASMB $32.44
- Technical
- Relative Strength Index (RSI)
- GAMB 31.43
- ASMB 61.76
- Support Level
- GAMB $7.55
- ASMB $27.07
- Resistance Level
- GAMB $7.84
- ASMB $32.44
- Average True Range (ATR)
- GAMB 0.26
- ASMB 1.70
- MACD
- GAMB -0.01
- ASMB 0.13
- Stochastic Oscillator
- GAMB 5.08
- ASMB 65.32
About GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.